Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arovella TherapeuticsASX:ALA +3.33% 3-Year EBITDA Growth Rate is 10.60% as of Dec. 2025, which is 4% below its 10-year median of 11.05. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Arovella Therapeutics ranks worse than 55.35% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 19.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Arovella Therapeutics was 48.80% per year. The lowest was -75.00% per year. And the median was 11.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Arovella Therapeutics 3-Year EBITDA Growth Rate Related Terms
ASX:ALA vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Arovella Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arovella Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Arovella Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.60% mean?
Arovella Therapeutics (ASX:ALA) has a 3-Year EBITDA Growth Rate of 10.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arovella Therapeutics and its competitors. This is near median its historical median of 11.05. According to the industry distribution chart, Arovella Therapeutics ranks #626 out of 1131 companies in the Biotechnology industry, placing it in the top 55.3%.
Is Arovella Therapeutics' 3-Year EBITDA Growth Rate too high?
Arovella Therapeutics' current 3-Year EBITDA Growth Rate of 10.60% is near median its 10-year median of 11.05. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Arovella Therapeutics' value of 10.60% is 28.9% below this industry median. Based on the distribution chart, Arovella Therapeutics ranks #626 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint.
How does Arovella Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arovella Therapeutics ranks #626 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Arovella Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Arovella Therapeutics' value of 10.60% is 28.9% below this benchmark. While the company's 10-year median is 11.05 vs. the industry median of 14.90, Arovella Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arovella Therapeutics's current 3-Year EBITDA Growth Rate of 10.60% is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arovella Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arovella Therapeutics's current 3-Year EBITDA Growth Rate is 10.60%, which is near median its own 10-year median of 11.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current 3-Year EBITDA Growth Rate of 10.60%. The current 3-Year EBITDA Growth Rate is 10.60%, which is near median its 10-year median of 11.05 and 28.9% below the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current 3-Year EBITDA Growth Rate is 10.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALA has been successfully added to your 
